Advertisement Cellectricon and AstraZeneca sign collaborative agreement - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Cellectricon and AstraZeneca sign collaborative agreement

Cellectricon, a provider of screening solutions for drug discovery, has announced a new collaborative agreement with AstraZeneca.

Under the agreement, Cellectricon will provide AstraZeneca with two of its new high throughput platforms, DynaflowHT, for ion channel screening. The DynaflowHT System will be launched and commercially available in 2009.

Jonas Ohlsson, CEO at Cellectricon, said: “Driven by solving bottlenecks in drug discovery, Cellectricon’s strategy is to bring state-of-the-art products for drug discovery and research to the market through world-class customer collaborations.”